See more : Space Shower Skiyaki Holdings Inc. (4838.T) Income Statement Analysis – Financial Results
Complete financial analysis of BrightPath Biotherapeutics Co., Ltd. (4594.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BrightPath Biotherapeutics Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Yamaha Motor Co., Ltd. (YMHAY) Income Statement Analysis – Financial Results
- Cummins Inc. (0I58.L) Income Statement Analysis – Financial Results
- CreditAccess Grameen Limited (CREDITACC.NS) Income Statement Analysis – Financial Results
- Manitou BF SA (MAOIF) Income Statement Analysis – Financial Results
- Classic Leasing & Finance Limited (CLFL.BO) Income Statement Analysis – Financial Results
BrightPath Biotherapeutics Co., Ltd. (4594.T)
About BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pluripotent stem cell derived regenerated NKT cell therapy for head and neck cancer; and BP2301, an autologous HER2 chimeric antigen receptor-T cell therapy for treating solid tumors sarcoma. Further, it is involved in discovering BP1200, an antibody targeting CD73; BP1210, an immune checkpoint inhibitory antibody; and other antibodies, such as BP1202, BP1206, and BP1211. The company was formerly known as GreenPeptide Co., Ltd. and changed its name to BrightPath Biotherapeutics Co., Ltd. in July 2017. BrightPath Biotherapeutics Co., Ltd. was founded in 2003 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 72.00K | 5.28M | 15.41M | 2.50M | 11.30M | 155.81M | 354.41M | 529.61M | 822.56M | 821.63M |
| Cost of Revenue | 413.00K | 1.90M | 3.32M | 1.15M | 4.47M | 70.70M | 315.17M | 524.91M | 771.66M | 766.62M |
| Gross Profit | -341.00K | 3.39M | 12.09M | 1.36M | 6.83M | 85.11M | 39.24M | 4.70M | 50.90M | 55.01M |
| Gross Profit Ratio | -473.61% | 64.11% | 78.47% | 54.27% | 60.47% | 54.62% | 11.07% | 0.89% | 6.19% | 6.69% |
| Research & Development | 775.56M | 1.17B | 1.14B | 1.41B | 1.48B | 1.39B | 1.15B | 816.78M | 848.99M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 74.00M | 67.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 419.80M | 231.20M | 0.00 | 0.00 |
| SG&A | 379.18M | 285.25M | 317.15M | 259.03M | 286.86M | 308.83M | 493.80M | 298.20M | 190.56M | 0.00 |
| Other Expenses | 0.00 | 241.00K | 89.00K | 98.00K | 301.00K | -10.27M | -81.00K | 12.56M | 13.96M | 86.09M |
| Operating Expenses | 1.15B | 1.47B | 1.49B | 1.73B | 1.83B | 1.75B | 1.60B | 1.12B | 1.04B | 547.19M |
| Cost & Expenses | 1.16B | 1.47B | 1.49B | 1.74B | 1.84B | 1.82B | 1.92B | 1.64B | 1.81B | 1.31B |
| Interest Income | 12.00K | 20.00K | 27.00K | 35.00K | 42.00K | 1.76M | 46.00K | 33.00K | 274.00K | 129.00K |
| Interest Expense | 1.40M | 61.00K | 362.00K | 9.10M | 0.00 | 0.00 | 0.00 | 13.65M | 16.00K | 6.49M |
| Depreciation & Amortization | 395.00K | 16.72M | 35.12M | 66.69M | 62.47M | 82.77M | 73.21M | 42.71M | 19.30M | 8.80M |
| EBITDA | -1.17B | -1.47B | -1.45B | -1.65B | -1.76B | -1.58B | -1.49B | -1.07B | -973.67M | -399.63M |
| EBITDA Ratio | -1,619,147.22% | -27,594.60% | -9,387.73% | -67,393.65% | -15,301.01% | -885.92% | -420.00% | -202.12% | -118.37% | -49.26% |
| Operating Income | -1.16B | -1.47B | -1.48B | -1.73B | -1.83B | -1.67B | -1.56B | -1.11B | -988.75M | -492.19M |
| Operating Income Ratio | -1,604,276.39% | -27,785.21% | -9,579.65% | -69,201.36% | -16,171.23% | -1,068.97% | -440.66% | -210.26% | -120.20% | -59.90% |
| Total Other Income/Expenses | -11.10M | -16.67M | -5.74M | 15.59M | -32.51M | -214.98M | -10.20M | -3.38M | -4.23M | 83.75M |
| Income Before Tax | -1.17B | -1.48B | -1.48B | -1.72B | -1.86B | -1.88B | -1.57B | -1.12B | -992.98M | -408.43M |
| Income Before Tax Ratio | -1,619,697.22% | -28,101.00% | -9,616.90% | -68,578.83% | -16,458.95% | -1,206.95% | -443.92% | -210.90% | -120.72% | -49.71% |
| Income Tax Expense | 1.90M | 1.90M | 2.42M | 2.42M | -2.09M | 3.79M | 5.12M | 5.07M | 1.49M | 4.00M |
| Net Income | -1.17B | -1.49B | -1.48B | -1.72B | -1.86B | -1.88B | -1.58B | -1.11B | -994.46M | -412.44M |
| Net Income Ratio | -1,622,336.11% | -28,136.99% | -9,632.61% | -68,675.48% | -16,440.48% | -1,209.38% | -445.00% | -210.28% | -120.90% | -50.20% |
| EPS | -18.21 | -24.90 | -28.55 | -36.14 | -44.20 | -44.95 | -41.25 | -32.74 | -35.28 | -20.34 |
| EPS Diluted | -18.21 | -24.90 | -28.55 | -36.14 | -44.20 | -44.95 | -41.25 | -32.74 | -35.28 | -20.34 |
| Weighted Avg Shares Out | 64.16M | 59.66M | 51.99M | 47.58M | 42.03M | 41.92M | 38.23M | 34.01M | 28.18M | 20.27M |
| Weighted Avg Shares Out (Dil) | 64.16M | 59.66M | 51.99M | 47.58M | 42.03M | 41.92M | 38.23M | 34.01M | 28.18M | 20.27M |
Source: https://incomestatements.info
Category: Stock Reports